PRA Health Sciences, Inc. (NASDAQ:PRAH) – Investment analysts at Jefferies Group reduced their Q4 2017 earnings per share estimates for shares of PRA Health Sciences in a report released on Wednesday. Jefferies Group analyst D. Windley now expects that the medical research company will post earnings per share of $0.89 for the quarter, down from their prior estimate of $0.90. Jefferies Group currently has a “Buy” rating and a $92.00 price objective on the stock.

PRAH has been the topic of a number of other research reports. Credit Suisse Group increased their price objective on PRA Health Sciences from $80.00 to $84.00 and gave the stock an “outperform” rating in a report on Tuesday. Bank of America Corporation started coverage on PRA Health Sciences in a report on Monday, June 26th. They set a “buy” rating and a $89.00 price objective on the stock. BidaskClub cut PRA Health Sciences from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. SunTrust Banks, Inc. reissued a “buy” rating on shares of PRA Health Sciences in a report on Wednesday. Finally, Robert W. Baird increased their price objective on PRA Health Sciences from $82.00 to $83.00 and gave the stock an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have issued a buy rating to the company’s stock. PRA Health Sciences has a consensus rating of “Buy” and an average target price of $78.00.

COPYRIGHT VIOLATION NOTICE: “Q4 2017 EPS Estimates for PRA Health Sciences, Inc. Decreased by Jefferies Group (PRAH)” was reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark law. The original version of this news story can be read at https://www.dailypolitical.com/2017/08/11/q4-2017-eps-estimates-for-pra-health-sciences-inc-decreased-by-jefferies-group-prah.html.

Shares of PRA Health Sciences (NASDAQ:PRAH) traded up 0.73% on Friday, hitting $74.35. The company had a trading volume of 349,447 shares. The firm has a market capitalization of $4.66 billion, a price-to-earnings ratio of 48.00 and a beta of 0.45. PRA Health Sciences has a 1-year low of $48.42 and a 1-year high of $80.99. The company has a 50 day moving average price of $75.21 and a 200 day moving average price of $67.10.

PRA Health Sciences (NASDAQ:PRAH) last issued its quarterly earnings results on Monday, August 7th. The medical research company reported $0.62 EPS for the quarter, missing the Zacks’ consensus estimate of $0.72 by $0.10. PRA Health Sciences had a return on equity of 21.17% and a net margin of 5.15%. The company had revenue of $457.90 million during the quarter, compared to the consensus estimate of $447.79 million. During the same quarter in the previous year, the business posted $0.63 EPS. The firm’s revenue for the quarter was up .5% on a year-over-year basis.

A number of institutional investors have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank raised its position in shares of PRA Health Sciences by 12.0% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,488 shares of the medical research company’s stock worth $112,000 after buying an additional 160 shares in the last quarter. Meeder Asset Management Inc. raised its position in shares of PRA Health Sciences by 144.0% in the second quarter. Meeder Asset Management Inc. now owns 1,535 shares of the medical research company’s stock worth $115,000 after buying an additional 906 shares in the last quarter. Envestnet Asset Management Inc. raised its position in shares of PRA Health Sciences by 232.3% in the first quarter. Envestnet Asset Management Inc. now owns 1,844 shares of the medical research company’s stock worth $121,000 after buying an additional 1,289 shares in the last quarter. Ameritas Investment Partners Inc. acquired a new position in shares of PRA Health Sciences during the first quarter worth $136,000. Finally, First Bank & Trust raised its position in shares of PRA Health Sciences by 1.7% in the first quarter. First Bank & Trust now owns 3,159 shares of the medical research company’s stock worth $206,000 after buying an additional 54 shares in the last quarter.

PRA Health Sciences Company Profile

PRA Health Sciences, Inc is a contract research organization. The Company provides outsourced clinical development services to the biotechnology and pharmaceutical industries. The Company offers therapeutic services in areas of pharmaceutical development, including oncology, central nervous system, inflammation and infectious diseases.

Receive News & Ratings for PRA Health Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for PRA Health Sciences Inc. and related companies with MarketBeat.com's FREE daily email newsletter.